Konstantinos Barmpagiannos

Dr. Konstantinos Barmpagiannos

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAthena Supports career advancement through high-quality, independent medical education, CPD, lifelong caree Myrou
Athena Supports career advancement through high-quality, independent medical education, CPD, lifelong caree Myrou
KBKonstantinos Barmpagiannos
Konstantinos Barmpagiannos
AIALIKI IOAKEIMIDOU
ALIKI IOAKEIMIDOU
CSChristos Savopoulos
Christos Savopoulos
Neurological diseases contribute significantly to disability and mortality, necessitating improved diagnostic and prognostic tools. Advances in molecular biomarkers at genomic, transcriptomic, epigenomic, and proteomic levels have facilitated early disease detection. Notably, neurofilament light chain (NfL) serves as a key biomarker of neurodegeneration, while liquid biopsy techniques enable non-invasive monitoring through exosomal tau, α-synuclein, and inflammatory markers. Artificial intelligence (AI) and multi-omics integration further enhance biomarker discovery, promoting precision medicine. A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science to identify studies (2010–2024) on molecular biomarkers in neurodegenerative and neuroinflammatory disorders. Key findings on genomic mutations, transcriptomic signatures, epigenetic modifications, and protein-based biomarkers were analyzed. The findings highlight the potential of liquid biopsy and multi-omics approaches in improving diagnostic accuracy and therapeutic stratification. Genomic, transcriptomic, and proteomic markers demonstrate utility in early detection and disease monitoring. AI-driven analysis enhances biomarker discovery and clinical application. Despite advancements, challenges remain in biomarker validation, standardization, and clinical implementation. Large-scale longitudinal studies are essential to ensure reliability. AI-powered multi-omics analysis may accelerate biomarker application, ultimately improving patient outcomes in neurological diseases.

1 October 2024 in Life
Verified
Journal Article
Open access
PDF file
GAGeorgios Anogianakis
Georgios Anogianakis
SDStylianos Daios
Stylianos Daios
NTNikolaos Topouzis
Nikolaos Topouzis
KBKonstantinos Barmpagiannos
Konstantinos Barmpagiannos
CKChristos Kaiafa
Christos Kaiafa
Christos SavopoulosChristos Savopoulos
Christos Savopoulos
Stroke is the third leading cause of death in the developed world and a major cause of chronic disability, especially among the elderly population. The major biomarkers of stroke which are the most promising for predicting onset time and independently differentiating ischemic from hemorrhagic and other stroke subtypes are at present limited to a few. This review aims to emphasize on the prognostic role of S100 calcium-binding protein b (S100B), and Glial Fibrillary Acidic Protein (GFAP) in patients with stroke. An electronic search of the published research from January 2000 to February 2024 was conducted using the MEDLINE, Scopus, and Cochrane databases. The implementation of S100B and GFAP in existing clinical scales and imaging modalities may be used to improve diagnostic accuracy and realize the potential of blood biomarkers in clinical practice. The reviewed studies highlight the potential of S100B and GFAP as significant biomarkers in the prognosis and diagnosis of patients with stroke and their ability of predicting long-term neurological deficits. They demonstrate high sensitivity and specificity in differentiating between ischemic and hemorrhagic stroke and they correlate well with stroke severity and outcomes. Several studies also emphasize on the early elevation of these biomarkers post-stroke onset, underscoring their value in early diagnosis and risk stratification. The ongoing research in this field should aim at improving patient outcomes and reducing stroke-related morbidity and mortality by developing a reliable, non-invasive diagnostic tool that can be easily implemented in several healthcare settings, with the ultimate goal of improving stroke management.

10 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AMAthena Supports career advancement through high-quality, independent medical education, CPD, lifelong caree Myrou
Athena Supports career advancement through high-quality, independent medical education, CPD, lifelong caree Myrou
KBKonstantinos Barmpagiannos
Konstantinos Barmpagiannos
AIALIKI IOAKEIMIDOU
ALIKI IOAKEIMIDOU
CSChristos Savopoulos
Christos Savopoulos
Background: Neurological diseases contribute significantly to disability and mortality, necessitating improved diagnostic and prognostic tools. Advances in molecular biomarkers at genomic, transcriptomic, epigenomic, and proteomic levels have facilitated early disease detection. Notably, neurofilament light chain (NfL) serves as a key biomarker of neurodegeneration, while liquid biopsy techniques enable non-invasive monitoring through exosomal tau, α-synuclein, and inflammatory markers. Artificial intelligence (AI) and multi-omics integration further enhance biomarker discovery, promoting precision medicine. Methods: A comprehensive literature review was conducted using PubMed, Scopus, and Web of Science to identify studies (2010–2024) on molecular biomarkers in neurodegenerative and neuroinflammatory disorders. Key findings on genomic mutations, transcriptomic signatures, epigenetic modifications, and protein-based biomarkers were analyzed. Results: Findings highlight the potential of liquid biopsy and multi-omics approaches in improving diagnostic accuracy and therapeutic stratification. Genomic, transcriptomic, and proteomic markers demonstrate utility in early detection and disease monitoring. AI-driven analysis enhances biomarker discovery and clinical application. Conclusion: Despite advancements, challenges remain in biomarker validation, standardization, and clinical implementation. Large-scale longitudinal studies are essential to ensure reliability. AI-powered multi-omics analysis may accelerate biomarker application, ultimately improving patient outcomes in neurological diseases.

29 May 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
KBKonstantinos Barmpagiannos
Konstantinos Barmpagiannos
Paschalis TheotokisPaschalis Theotokis
Paschalis Theotokis
SPSteven Petratos
Steven Petratos
MPMaurice Pagnin
Maurice Pagnin
OEOfira Einstein
Ofira Einstein
NGNikolaos Grigoriadis
Nikolaos Grigoriadis
Neuroglial cells, and especially astrocytes, constitute the most varied group of central nervous system (CNS) cells, displaying substantial diversity and plasticity during development and in disease states. The morphological changes exhibited by astrocytes during the acute and chronic stages following CNS injury can be characterized more precisely as a dynamic continuum of astrocytic reactivity. Different subpopulations of reactive astrocytes may be ascribed to stages of degenerative progression through their direct pathogenic influence upon neurons, neuroglia, the blood-brain barrier, and infiltrating immune cells. Multiple sclerosis (MS) constitutes an autoimmune demyelinating disease of the CNS. Despite the previously held notion that reactive astrocytes purely form the structured glial scar in MS plaques, their continued multifaceted participation in neuroinflammatory outcomes and oligodendrocyte and neuronal function during chronicity, suggest that they may be an integral cell type that can govern the pathophysiology of MS. From a therapeutic-oriented perspective, astrocytes could serve as key players to limit MS progression, once the integral astrocyte–MS relationship is accurately identified. This review aims toward delineating the current knowledge, which is mainly focused on immunomodulatory therapies of the relapsing–remitting form, while shedding light on uncharted approaches of astrocyte-specific therapies that could constitute novel, innovative applications once the role of specific subgroups in disease pathogenesis is clarified.

23 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DVDimitra Vlachopoulou
Dimitra Vlachopoulou
CBCharalampos Balomenakis
Charalampos Balomenakis
AKAnastasios Kartas
Anastasios Kartas
Athanasios SamarasAthanasios Samaras
Athanasios Samaras
APAndreas S Papazoglou
Andreas S Papazoglou
George GiannakoulasGeorge Giannakoulas
George Giannakoulas
Background: Atrial fibrillation (AF) and chronic obstructive pulmonary disease (COPD) have been independently associated with increased mortality; however, there is no evidence regarding beta-blocker cardioselectivity and long-term outcomes in patients with AF and concurrent COPD. Methods: This post hoc analysis of the MISOAC-AF randomized trial (NCT02941978) included patients hospitalized with comorbid AF. At discharge, all patients were classified according to the presence of COPD; patients with COPD on beta-blockers were classified according to beta-blocker cardioselectivity. Adjusted hazard ratios (aHRs) were calculated by using multivariable Cox regression models. The primary outcome was all-cause mortality, and the secondary outcomes were cardiovascular mortality and hospitalizations. Results: Of 1103 patients with AF, 145 (13%) had comorbid COPD. Comorbid COPD was associated with an increased risk of all-cause (aHR, 1.33; 95% confidence interval (CI), 1.02 to 1.73) and cardiovascular mortality (aHR 1.47; 95% CI, 1.10 to 1.99), but not with increased risk of hospitalizations (aHR 1.10; 95% CI, 0.82 to 1.48). The use of cardioselective versus non-cardioselective beta-blockers was associated with similar all-cause mortality (aHR 1.10; 95% CI, 0.63 to 1.94), cardiovascular mortality (aHR 1.33; 95% CI, 0.71 to 2.51), and hospitalizations (aHR 1.65; 95% CI 0.80 to 3.38). Conclusions: In recently hospitalized patients with AF, the presence of COPD was independently associated with increased risk of all-cause and cardiovascular mortality. No difference between cardioselective and non-cardioselective beta-blockers, regarding clinical outcomes, was identified.

26 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Athanasios SamarasAthanasios Samaras
Athanasios Samaras
Dimitrios V. MoysidisDimitrios V. Moysidis
Dimitrios V. Moysidis
APAndreas S Papazoglou
Andreas S Papazoglou
Georgios RampidisGeorgios Rampidis
Georgios Rampidis
KBKonstantinos Barmpagiannos
Konstantinos Barmpagiannos
George GiannakoulasGeorge Giannakoulas
George Giannakoulas
Background/Objectives: Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a heterogenous clinical entity that differs in pathophysiology, treatment, and prognosis from myocardial infarction with obstructive coronary artery disease (MI-CAD) and MINOCA mimickers, such as myocarditis or Takotsubo syndrome. This study aimed to compare the clinical characteristics, imaging findings, management strategies, and long-term outcomes of patients with true MINOCA, MI-CAD, and MINOCA mimickers. Methods: This retrospective cohort study included 1596 patients hospitalized with acute myocardial infarction (AMI) between 2012 and 2024 at a tertiary university hospital. Patients were classified as having true MINOCA, MI-CAD, or MINOCA mimickers based on coronary angiography and advanced cardiac imaging. Data included clinical and laboratory variables, echocardiography, cardiac magnetic resonance (CMR), and coronary computed tomography angiography (CCTA). All-cause mortality was analyzed using Cox regression. Results: Of 1596 AMI patients, 111 (7.0%) had true MINOCA, 1359 (85.1%) had MI-CAD, and 127 (8.0%) had MINOCA mimickers. Mimicker patients were significantly younger and had fewer cardiovascular risk factors. True MINOCA was more frequent in females and associated with preserved left ventricular ejection fraction and lower high-sensitivity troponin T levels compared to MI-CAD. CMR and CCTA contributed to etiological clarification in over 70% of MINOCA and mimicker patients. High-risk plaque features were observed in 42.9% of CCTA scans, suggesting but not confirming an atherosclerotic mechanism. Long-term all-cause mortality in MINOCA was similar to MI-CAD (32.1% vs. 30.9%, p = 0.764) and significantly higher than in mimickers (5.9%, p < 0.001). Conclusions: True MINOCA is a distinct clinical entity with diagnostic and prognostic implications. Its comparable mortality to MI-CAD highlights the need for accurate diagnosis and targeted secondary prevention strategies.